Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

TRACON Pharmaceuticals Inc. - news published 162 - readings 3.189

BACK

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Announces it Will Wind Down Operations

The text version of this document is not available. You can access the original document here . Attachments Original Link Permalink Disclaimer TRACON Pharmaceuticals Inc. published this content on 30 July 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 30 July 2024 21:10:25 UTC .

30.07.2024

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Announces it Will Wind Down Operations Form 8 K

TRACON Pharmaceuticals Announces it Will Wind Down Operations San Diego, CA - July 30, 2024 - TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, ...

30.07.2024

TRACON Pharmaceuticals Inc.

Failure to Satisfy Listing Rule Form 8 K

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on June 11, 2024, TRACON Pharmaceuticals, Inc. (the "Company") received a determination letter (the "Delisting Notification") from Nasdaq stating that the Nasdaq Hearings Panel (the "Panel") has determined to deli ...

16.07.2024

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

The text version of this document is not available. You can access the original document here . Attachments Original Link Permalink Disclaimer TRACON Pharmaceuticals Inc. published this content on 01 July 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 01 July 2024 13:19:33 UTC .

01.07.2024

TRACON Pharmaceuticals Inc.

Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 19, 2024, David Lazar notified the Company that he voluntarily resigned from his position as Chief Business Development Officer of the Company, effective June 19, 2024. Mr. Lazar's resignation is not a result of an ...

21.06.2024

TRACON Pharmaceuticals Inc.

Failure to Satisfy Listing Rule Form 8 K

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed by TRACON Pharmaceuticals, Inc. (the "Company"), pursuant to its Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on April 10, 2024, on March 20, 2024, the Nasdaq Hearings Panel (the & ...

12.06.2024

TRACON Pharmaceuticals Inc.

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients June 11, 2024 12:00 PM EDT Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Bea ...

11.06.2024

TRACON Pharmaceuticals Inc.

OTCQB Certification

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer TRACON Pharmaceuticals Inc. published this content on 28 May 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 28 May 2024 15:35:59 UTC .

28.05.2024

TRACON Pharmaceuticals Inc.

Q1 2024 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36818 TRACON Pharmaceuticals, Inc. (Exact na ...

15.05.2024

TRACON Pharmaceuticals Inc.

Quarterly Report for Quarter Ending MARCH 31, 2024 (Form 10-Q)

10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36818 TRACON Pharmaceuticals, I ...

14.05.2024

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update - Form 8-K

TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update San Diego, CA - May 14, 2024 - TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other l ...

14.05.2024

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update May 14, 2024 8:01 PM EDT SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient,CRO-independent product development platform to advance its pipeline of novel targeted cancer the ...

14.05.2024

TRACON Pharmaceuticals Inc.

Initial Statement of Beneficial Ownership - Form 3

Ownership Submission FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per respo ...

13.05.2024

TRACON Pharmaceuticals Inc.

Management Change/Compensation - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 8, 2024, the board of directors of TRACON Pharmaceuticals, Inc. (the "Company") appointed, and the Company entered into an employment agreement (the "Agreement") with, David Lazar as Chief Busine ...

13.05.2024

TRACON Pharmaceuticals Inc.

TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 May 7, 2024 8:01 PM EDT SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient,CRO-independent product development platform to advance its pipeline of novel targeted cancer the ...

07.05.2024

TRACON Pharmaceuticals Inc. - news published 162 - readings 3.189

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Announces it Will Wind Down Operations

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Announces it Will Wind Down Operations Form 8 K

TRACON Pharmaceuticals Inc.

Failure to Satisfy Listing Rule Form 8 K

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

TRACON Pharmaceuticals Inc.

Management Change/Compensation Form 8 K

TRACON Pharmaceuticals Inc.

Failure to Satisfy Listing Rule Form 8 K

TRACON Pharmaceuticals Inc.

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

TRACON Pharmaceuticals Inc.

OTCQB Certification

TRACON Pharmaceuticals Inc.

Q1 2024 10-Q

TRACON Pharmaceuticals Inc.

Quarterly Report for Quarter Ending MARCH 31, 2024 (Form 10-Q)

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update - Form 8-K

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals Inc.

Initial Statement of Beneficial Ownership - Form 3

TRACON Pharmaceuticals Inc.

Management Change/Compensation - Form 8-K

TRACON Pharmaceuticals Inc.

TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member